RAMADAN

Showing posts with label Covid-19. Show all posts
Showing posts with label Covid-19. Show all posts

Saturday, July 16, 2022

New Psychiatric Disorders Appeared in Healthy Individuals Following Vaccination

As of early July 2022, 66 percent of the world’s population has been vaccinated with the COVID-19 vaccines. As more people are getting vaccinated, reports on adverse events and even side effects continue to emerge. Not only injuries on vital organs have been reported, but also psychiatric disorders have been reported as well. As off today, there are a total of 10 pieces of medical literature that have reported cases of newly developed mental illness after the patients were inoculated with the COVID-19 jabs.

اعتبارًا من أوائل يوليو 2022 ، قد تم تطعيم 66 بالمائة من سكان العالم بلقاحات COVID-19. مع تلقي المزيد من الناس للتطعيم ، تستمر التقارير في الظهور عن الأحداث الضارة وحتى الآثار الجانبية للقاحات. لم يتم الإبلاغ عن إصابات في الأعضاء الحيوية فحسب ، بل تم الإبلاغ أيضًا عن اضطرابات نفسية. في هذا اليوم ، هناك ما مجموعه 10 مقالات طبية أبلغت ونشرت عن حالات أمرض عقلية تم تطويرها حديثًا بعد تلقيح المرضى بلقاحات COVID-19. حيث  ظهرت اضطرابات نفسية جديدة في الأفراد الأصحاء بعد التطعيم

Monday, June 20, 2022

دراسة تتوصل إلى أن لقاح كوفيد-19 من فايزر ينتقل إلى خلايا الكبد ويتحول إلى حمض نووي دي إن إيه- كل يوم يكتشف أن اللقاحات لا فائدة منها ومع هذا مصرين على إعطائها للناس ونحن كالعادة تابعين

 

Pfizer’s COVID-19 Vaccine Goes Into Liver Cells and Is Converted to DNA: Study

BY MEILING LEE TIMEMARCH 1, 2022 PRINT

The messenger RNA (mRNA) from Pfizer’s COVID-19 vaccine is able to enter human liver cells and is converted into DNA, according to Swedish researchers at Lund University.

The researchers found that when the mRNA vaccine enters the human liver cells, it triggers the cell’s DNA, which is inside the nucleus, to increase the production of the LINE-1 gene expression to make mRNA.

The mRNA then leaves the nucleus and enters the cell’s cytoplasm, where it translates into LINE-1 protein. A segment of the protein called the open reading frame-1, or ORF-1, then goes back into the nucleus, where it attaches to the vaccine’s mRNA and reverse transcribes into spike DNA.

Reverse transcription is when DNA is made from RNA, whereas the normal transcription process involves a portion of the DNA serving as a template to make an mRNA molecule inside the nucleus.

“In this study we present evidence that COVID-19 mRNA vaccine BNT162b2 is able to enter the human liver cell line Huh7 in vitro,” the researchers wrote in the study, published in Current Issues of Molecular Biology. “BNT162b2 mRNA is reverse transcribed intracellularly into DNA as fast as 6 [hours] after BNT162b2 exposure.”

BNT162b2 is another name for the Pfizer-BioNTech COVID-19 vaccine that is marketed under the brand name Comirnaty.

The whole process occurred rapidly within six hours. The vaccine’s mRNA converting into DNA and being found inside the cell’s nucleus is something that the Centers for Disease Control and Prevention (CDC) said would not happen.

“The genetic material delivered by mRNA vaccines never enters the nucleus of your cells,” the CDC said on its web page titled “Myths and Facts about COVID-19 Vaccines.”

This is the first time that researchers have shown in vitro or inside a petri dish how an mRNA vaccine is converted into DNA on a human liver cell line, and is what health experts and fact-checkers said for over a year couldn’t occur.

The CDC says that the “COVID-19 vaccines do not change or interact with your DNA in any way,” claiming that all of the ingredients in both mRNA and viral vector COVID-19 vaccines (administered in the United States) are discarded from the body once antibodies are produced. These vaccines deliver genetic material that instructs cells to begin making spike proteins found on the surface of SARS-CoV-2 that causes COVID-19 to produce an immune response.

Pfizer didn’t comment on the findings of the Swedish study and said only that its mRNA vaccine does not alter the human genome.

“Our COVID-19 vaccine does not alter the DNA sequence of a human cell,” a Pfizer spokesperson told The Epoch Times in an email. “It only presents the body with the instructions to build immunity.”

More than 215 million or 64.9 percent of Americans are fully vaccinated as of Feb. 28, with 94 million having received a booster dose.

Autoimmune Disorders

The Swedish study also found spike proteins expressed on the surface of the liver cells that researchers say may be targeted by the immune system and possibly cause autoimmune hepatitis, as “there [have] been case reports on individuals who developed autoimmune hepatitis after BNT162b2 vaccination.”

The authors of the first reported case of a healthy 35-year-old female who developed autoimmune hepatitis a week after her first dose of the Pfizer COVID-19 vaccine said that there is a possibility that “spike-directed antibodies induced by vaccination may also trigger autoimmune conditions in predisposed individuals” as it has been shown that “severe cases of SARS-CoV-2 infection are characterized by an autoinflammatory dysregulation that contributes to tissue damage,” which the virus’s spike protein appears to be responsible for.

Spike proteins may circulate in the body after an infection or injection with a COVID-19 vaccine. It was assumed that the vaccine’s spike protein would remain mostly at the injection site and last up to several weeks like other proteins produced in the body. But studies are showing that is not the case.

The Japanese regulatory agency’s biodistribution study  of the Pfizer vaccine showed that some of the mRNAs moved from the injection site and through the bloodstream, and were found in various organs such as the liver, spleen, adrenal glands, and ovaries of rats 48 hours following injection.

In a different study, the spike proteins made in the body after receiving a Pfizer COVID-19 shot have been found on tiny membrane vesicles called exosomes—that mediate cell-to-cell communication by transferring genetic materials to other cells—for at least four months after the second vaccine dose.

The persistence of the spike protein in the body “raises the prospect of sustained inflammation within and damage to organs which express the spike protein,” according to experts at Doctors for COVID Ethics, an organization consisting of physicians and scientists “seeking to uphold medical ethics, patient safety, and human rights in response to COVID-19.”

“As long as the spike protein can be detected on cell-derived membrane vesicles, the immune system will be attacking the cells that release these vesicles,” they said.

Dr. Peter McCullough, an internist, cardiologist, and epidemiologist, wrote on Twitter that the Swedish study’s findings have “enormous implications of permanent chromosomal change and long-term constitutive spike synthesis driving the pathogenesis of a whole new genre of chronic disease.”

Whether the findings of the study will occur in living organisms or if the DNA converted from the vaccine’s mRNA will integrate with the cell’s genome is unknown. The authors said more investigations are needed, including in whole living organisms such as animals, to better understand the potential effects of the mRNA vaccine.

“At this stage, we do not know if DNA reverse transcribed from BNT162b2 is integrated into the cell genome. Further studies are needed to demonstrate the effect of BNT162b2 on genomic integrity, including whole genome sequencing of cells exposed to BNT162b2, as well as tissues from human subjects who received BNT162b2 vaccination,” the authors said.

 


Thursday, May 19, 2022

الدراسة أثبتت أن لقاح فايزر ضد كورونا متحور أميكرون يتلاشى بعد عدة أسابيع قليلة!!!!

 

Pfizer’s COVID Vaccine Protection Against Omicron Fades After a Few Weeks: Study

By Jack Phillips
 
May 16, 2022 Updated: May 16, 2022

الدراسة أثبتت أن لقاح فايزر ضد كورونا متحور أميكرون يتلاشى بعد عدة أسابيع قليلة

The protection afforded against the Omicron coronavirus variant fades quickly after a second and third dose of Pfizer–BioNtech’s COVID-19 vaccine, according to a peer-reviewed study published in the JAMA Network.

الحماية الممنوحة ضد متغير فيروس كورونا أوميكرون تتلاشى بسرعة بعد الجرعة الثانية والثالثة من لقاح  COVID-19 من شركة  فايزر Pfizer – BioNtech ، وفقًا لدراسة تمت مراجعتها من قِبل النشرات العلمية ونشرت في شبكة JAMA.

A Danish study published in the JAMA Network on May 13 found that there was a rapid decline in Omicron-specific serum neutralizing antibodies only a few weeks after the administration of the second and third doses of the vaccine.

وجدت دراسة دنماركية نُشرت في شبكة JAMA في 13 مايو أن هناك انخفاضًا سريعًا في الأجسام المضادة المعادلة لمصل أوميكرون بعد أسابيع قليلة فقط من إعطاء الجرعتين الثانية والثالثة من اللقاح.

 

The study evaluated 128 adults who were vaccinated, and of that number, 73 people received two doses of the Pfizer vaccine, and 55 people received three doses between January 2021 and October 2021 or were previously infected before February 2021, and then vaccinated.

قامت الدراسة بتقييم 128 بالغًا تم تطعيمهم ، ومن هذا العدد تلقى 73 شخصًا جرعتين من لقاح فايزر ، وتلقى 55 شخصًا ثلاث جرعات بين يناير 2021 وأكتوبر 2021 أو أصيبوا سابقًا قبل فبراير 2021 ، ثم تم تطعيمهم.

“Our study found a rapid decline in Omicron-specific serum neutralizing antibody titers only a few weeks after the second and third doses,” an abstract of the study reads. “The observed decrease in population neutralizing antibody titers corresponds to the decrease in vaccine efficacy against polymerase chain reaction–confirmed Omicron infection in Denmark and symptomatic Omicron infection in the United Kingdom.”

ملخص الدراسة: "وجدت دراستنا انخفاضًا سريعًا في عيار الأجسام المضادة الخاصة بأوميكرون المصل المحدد بعد أسابيع قليلة فقط من الجرعتين الثانية والثالثة". "الانخفاض الملحوظ في عيار الأجسام المضادة المعادلة للسكان يتوافق مع انخفاض فعالية اللقاح ضد تفاعل البلمرة المتسلسل - عدوى Omicron المؤكدة في الدنمارك وعدوى Omicron المصحوبة بأعراض في المملكة المتحدة."

The antibody levels, which are associated with protection against future infections, dropped within a few weeks of getting the vaccine doses. They were also much lower than the antibodies specific to the Delta and original COVID-19 strains, according to the study.

انخفضت مستويات الأجسام المضادة ، المرتبطة بالحماية من العدوى المستقبلية ، في غضون أسابيع قليلة من الحصول على جرعات اللقاح. كانت أيضًا أقل بكثير من الأجسام المضادة الخاصة بدلتا وسلالات COVID-19 الأصلية ، وفقًا للدراسة.

The proportion of Omicron-specific antibodies fell to 53 percent between the eighth and tenth week from 76 percent four weeks after the second dose. At weeks 12 to 14, these levels dropped even more to only 19 percent, according to the study.

انخفضت نسبة الأجسام المضادة الخاصة بأوميكرون إلى 53 بالمائة بين الأسبوعين الثامن والعاشر من 76 بالمائة بعد أربعة أسابيع من الجرعة الثانية. في الأسابيع من 12 إلى 14 ، انخفضت هذه المستويات أكثر إلى 19 في المائة فقط ، وفقًا للدراسة.

 

Those antibodies increased with a third dose, increasing 21-fold three weeks after the dose before dropping to eightfold at week four. But with the third dose, antibody levels dropped as early as three weeks, falling 5.4-fold between the third and eighth week, the researchers said.

زادت هذه الأجسام المضادة بجرعة ثالثة ، وزادت بمقدار 21 ضعفًا بعد ثلاثة أسابيع من الجرعة قبل أن تنخفض إلى ثمانية أضعاف في الأسبوع الرابع. لكن مع الجرعة الثالثة ، انخفضت مستويات الأجسام المضادة في وقت مبكر يصل إلى ثلاثة أسابيع ، وانخفضت بمقدار 5.4 أضعاف بين الأسبوعين الثالث والثامن ، كما قال الباحثون.

They concluded that it may be needed to provide additional booster doses to combat the Omicron variant, which emerged last fall, primarily among older individuals.

وخلصوا إلى أنه قد تكون هناك حاجة لتوفير جرعات معززة إضافية لمكافحة متغير أوميكرون  الذي ظهر في الخريف الماضي ، بشكل أساسي بين الأفراد الأكبر سنًا.

However, a study from Israeli researchers published in early April in the New England Journal of Medicine found that a fourth dose, or a second booster, of the Pfizer vaccine, doesn’t offer strong protection.

“Overall, these analyses provided evidence for the effectiveness of a fourth vaccine dose against severe illness caused by the omicron variant, as compared with a third dose administered more than 4 months earlier,” the study’s authors wrote at the time, after analyzing data from the Israeli Ministry of Health. “For confirmed infection, a fourth dose appeared to provide only short-term protection and a modest absolute benefit.”

Friday, May 6, 2022

هيئة الغذاء والدواء الأمريكية تقيد إستخدام لقاح جونسون لأنه يسبب تجلطات دموية



Johnson & Johnson Covid-19 Vaccine Use Limited By US Food And Drug Administration Advisory

The FDA said in a statement that the change is because of a risk of a clotting condition called thrombosis with thrombocytopenia syndrome (TTS) from use of the vaccine.
Thursday’s announcement is sure to fuel further concerns among those who have resisted Covid-19 vaccinations. Many people have cited concerns about vaccinations that were rushed to market without the usual years-long vetting on potential long-term effects. While those fears have been derided as “conspiracy theories,” today’s ruling will give pause on whether the resistance was grounded in logic.


“We’ve been closely monitoring the Janssen COVID-19 Vaccine and occurrence of TTS following its administration and have used updated information from our safety surveillance systems to revise the EUA,” said Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research. “We recognize that the Janssen COVID-19 Vaccine still has a role in the current pandemic response in the United States and across the global community. … Today’s action demonstrates the robustness of our safety surveillance systems and our commitment to ensuring that science and data guide our actions.”


The new marching orders applies to first shots and any boosters.


Despite the warning, the FDA said the J&J vaccine’s blood clotting problem is still better than not being vaccinated. It gave several examples of those who may still benefit, including: :


Those who had a severe allergic reaction to an mRNA vaccine, such as those from Pfizer/BioNTech or Moderna;


Those with personal concerns about the mRNA vaccines who would remain unvaccinated without the J&J vaccine;


Those with limited access to mRNA Covid-19 vaccines.


Moe than 18.7 million doses of the J&J vaccine have been administered in the US, according to the US Centers for Disease Control and Prevention. It estimated that 7.7% of those who received the J&J vaccine are considered fully vaccinated.


In an updated fact sheet on the vaccine, the FDA says that 15% of TTS cases have been fatal.


The agency’s updated analysis of the vaccine includes cases reported to its Vaccine Adverse Events Reporting System (VAERS) database through March 18. The FDA says it has confirmed 60 cases of TTS, including nine deaths.

Wednesday, December 8, 2021

عجيب أمر شركات اللقاحات! اللقاح فعال لمتحور أوميكرون ، بعدها بكام سطر مش أكيد فاعليته بعدها بكام سطر ممكن عمل لقاح جديد خاص للمتحور في خلال 6 أسابيع! أيهم الصحيح

 


Pfizer says booster dose of vaccine protects against omicron variant


A booster dose of the Pfizer-BioNTech Covid-19 vaccine appears to provide strong protection against the omicron variant, the companies announced Wednesday.

أعلنت شركة فايزر يوم الأربعاء أن الجرعة المعززة من لقاحها بايو إن تيك كوفيد-19 يوفر حماية قوية لمتحور أوميكرون


They said a third dose of their vaccine provides a similar level of neutralizing antibodies to omicron, comparable to two doses against the original coronavirus and other variants that have emerged.

Blood samples from those who received only the primary series of the vaccine, on average, did see a 25-fold drop in antibodies against the new variant, indicating that two doses of the vaccine may not be sufficient to protect against infection with omicron.
عينات الدم التي تم أخذها من الأشخاص الذين حصلوا على اللقاح بالسلسلة الأولى له ، أظهرت أنخفاضاً في الأجسام المضادة 25 ضعفاً للمتحور الجديد ، مما يشير إلى أن الجرعتين من اللقاح قد لا تكون كافية للحماية  والوقاية من الأصابة بمتحور أوميكرون

As the highly mutated omicron variant, first identified in South Africa, spreads around the globe, scientists are racing to determine what whether the available vaccines will work against it.


The companies said the results are preliminary. The findings were detailed in a press release, and the full data have not yet been made available for other scientists to scrutinize.

But lab studies are only one piece of the puzzle.
Other data are also needed to determine whether a new vaccine is needed. Scientists need to understand transmissible the omicron variant is (early indications suggest it's more contagious than the delta variant) as well as how sick it makes people (early data suggests the illness caused by the variant is milder).
المعلومات الأخرى سوف تحدد هل نحتاج  لقاح جديد

The results from Pfizer-BioNTech are the first announced by vaccine makers. Tuesday, a South Africa research institute also released lab results on how the Pfizer vaccine fared against omicron, showing about a fortyfold reduction in vaccine-induced antibodies that could neutralize the new variant. That study didn't look at booster shots, however.

Pfizer-BioNTech has previously said it could develop a variant-specific vaccine within six weeks and ship initial batches within 100 days.
وسبق أن أعلنت شركة فايزر أنها قد تقوم بتطوير لقاح محدد للمتحور خلال ستة أسابيع وتقوم بتوريد دفعات أولية خلال 100 يوم

Moderna and Johnson & Johnson are expected to release lab results from the omicron variant in the coming days. Academic research institutions are also looking into how well the vaccine works against omicron.

Monday, December 6, 2021

https://www.cdc.gov/coronavirus/2019-ncov/variants/omicron-variant.html

 

What We Know about Omicron

Infection and Spread

  • How easily does Omicron spread? The Omicron variant likely will spread more easily than the original SARS-CoV-2 virus and how easily Omicron spreads compared to Delta remains unknown. CDC expects that anyone with Omicron infection can spread the virus to others, even if they are vaccinated or don’t have symptoms.
  • من المحتمل أن ينتشر متحور اوميكرون بسهولة أكبر من فيروس كوفيد-19 الأصلي وبالنسبة لمدى سهولة أنتشار أوميكرون مقارنة ب متحور دلتا، لازال غير معروف للعلماء، ويتوقع مركز التحكم والسيطرة على الأمراض أن آي شخص مصاب بعدوى اوميكرون يمكن أن ينشر الفيروس للأخرين حتى لمن حصل على التطعيمين أو من لا يظهر عليه أعراض

  • Will Omicron cause more severe illness? More data are needed to know if Omicron infections, and especially reinfections and breakthrough infections in people who are fully vaccinated, cause more severe illness or death than infection with other variants.
  • هناك حاجة للمزيدمن المعلومات والبيانات لمعرفة ما إذا كانت عدوى أميكرون العدوى والإصابات في الأشخاص الذين تم تطعيمهم تسبب مرضاً شديداً أو وفاة بطريقة أكبر من المتحورات السابقة
  • Will vaccines work against Omicron? Current vaccines are expected to protect against severe illness, hospitalizations, and deaths due to infection with the Omicron variant. However, breakthrough infections in people who are fully vaccinated are likely to occur. With other variants, like Delta, vaccines have remained effective at preventing severe illness, hospitalizations, and death. The recent emergence of Omicron further emphasizes the importance of vaccination and boosters.
  • Will treatments work against Omicron? Scientists are working to determine how well existing treatments for COVID-19 work. Based on the changed genetic make-up of Omicron, some treatments are likely to remain effective while others may be less effective.
  • هل ستكون العلاجات واللقاحات الحالية فعالة مع متحور أميكرون؟
  • مازال العلماء يعملون على تحديد مدى نجاح العلاجات الحالية ل كوفيد-19 بناءً على التركيب الجيني المتغير لاوميكرون ، ومن المرجح أن تظل بعض تلك العلاجات فعالة بينما قد يكون البعض الآخر أقل فاعلية. ومن عندي أول لا فاعليه لها على الإطلاق

We have the Tools to Fight Omicron

Vaccines remain the best public health measure to protect people from COVID-19, slow transmission, and reduce the likelihood of new variants emerging. COVID-19 vaccines are highly effective at preventing severe illness, hospitalizations, and death. Scientists are currently investigating Omicron, including how protected fully vaccinated people will be against infection, hospitalization, and death. CDC recommends that everyone 5 years and older protect themselves from COVID-19 by getting fully vaccinated. CDC recommends that everyone ages 18 years and older should get a booster shot at least two months after their initial J&J/Janssen vaccine or six months after completing their primary COVID-19 vaccination series of Pfizer-BioNTech or Moderna.

Masks offer protection against all variants. CDC continues to recommend wearing a mask in public indoor settings in areas of substantial or high community transmission, regardless of vaccination status. CDC provides advice about masks for people who want to learn more about what type of mask is right for them depending on their circumstances.

Tests can tell you if you are currently infected with COVID-19. Two types of tests are used to test for current infection: nucleic acid amplification tests (NAATs) and antigen tests. NAAT and antigen tests can only tell you if you have a current infection. Individuals can use the COVID-19 Viral Testing Tool to help determine what kind of test to seek. Additional tests would be needed to determine if your infection was caused by Omicron. Visit your state, tribal, local, or territorial health department’s website to look for the latest local information on testing.

Self-tests can be used at home or anywhere, are easy to use, and produce rapid results. If your self-test has a positive result, stay home or isolate for 10 days, wear a mask if you have contact with others, and call your healthcare provider. If you have any questions about your self-test result, call your healthcare provider or public health department.

Until we know more about the risk of Omicron, it is important to use all tools available to protect yourself and others.

What CDC is Doing to Learn about Omicron

Virus Characteristics

CDC scientists are working with partners to gather data and virus samples that can be studied to answer important questions about the Omicron variant. Scientific experiments have already started. CDC will provide updates as soon as possible.

Variant Surveillance

In the United States, CDC uses genomic surveillance to track variants of SARS-CoV-2, the virus that causes COVID-19 to more quickly identify and act upon these findings to best protect the public’s health. CDC established multiple ways to connect and share genomic sequence data being produced by CDC, public health laboratories, and commercial diagnostic laboratories within publicly accessible databases maintained by the National Center for Biotechnology Informationexternal icon (NCBI) and the Global Initiative on Sharing Avian Influenza Dataexternal icon (GISAID). CDC’s national genomic surveillance can detect a variant that is circulating at 0.1% frequency with 99% statistical confidence.

 

Friday, October 8, 2021

Pfizer's COVID-19 immunity protection diminishes after 2 months المناعة تتضائل إلى 20% بعد 4 شهور حتى بعد جرعتين من لقاح فايزر

 

Pfizer's COVID-19 immunity protection diminishes after 2 months, and it can reach as low as 20% after 4 months: studies



  • Two recent studies found that Pfizer's immunity protection diminishes rapidly a few months after a person has their second dose.

  • بعد القيام بدراستين حديثتين وجد أن الحماية المناعية للقاح فايزر تتضائل سريعاً في أشهر قليلة للأفراد الذين حصلوا على الجرعة الثانية

  • However, one study noted that the vaccine's protection against death and hospitalization still remained as high as 96%.

  • بالرغم من ذلك فإن أحد الدراستين أشارت أن حماية اللقاح ضد الوفاة أو دخول المشفى مازالت مرتفة إلى 96% تقريبا

  • The studies affirm Pfizer's earlier comments that its vaccines may not defend against COVID-19 infection as effectively over time.

  • الدراسات أكدت تعقيبات فايزر السابقة أن لقاحهم ربما لا يحمي من عدوى كوفيد-19 بفاعلية مع مرور الوقت

COVID-19 immunity protection from two doses of the Pfizer vaccine starts dwindling after about two month, still, the shots remain effective in guarding against hospitalization and death, according to a pair of studies published in the New England Journal of Medicine on Wednesday.

The new findings affirm what Pfizer, Moderna, and the Centers for Disease Control and Prevention have indicated in recent weeks - that the vaccines' ability to protect the body from coronavirus infection may wane over time. Last month, the Food and Drug Administration authorized Pfizer booster shots for older or more vulnerable people.

In the first study, researchers from Qatar found that Pfizer's immunity protection drops to as low as 20% just four months after a person receives their second dose. They based their report on observations of infections among Qatar's over 900,000 vaccinated people.

The researchers found that Pfizer's protection against infection was "negligible" shortly after the first dose, but jumps to 36.8% three weeks later. When people receive their second dose, immunity protection increases to 77.5% after about a month.

But once that month is over, Pfizer's immunity effectiveness declines steadily, hovering at around 20% after the four-month mark, per the researchers.

"These findings suggest that a large proportion of the vaccinated population could lose its protection against infection in the coming months, perhaps increasing the potential for new epidemic waves," wrote the report.

Still, Pfizer's protection against hospitalization and death remained "robust" at 90% or higher for six months after the second dose, it said. The report also noted that its findings may not apply well to countries with older populations, since Qatar's population is relatively young with only 9% of its people being 50 or older.

The other study, conducted in Israel, looked at 4,868 healthcare workers. It reported that people have substantially decreased COVID-19 antibodies just six months after receiving their second dose of Pfizer's vaccine.

The drop is especially prominent among men, the elderly above 65, and those with weakened immune systems.

In comparison, vaccines for other conditions such as mumps, measles, and rubella only show small decreases of about 5% to 10% each year in neutralizing antibody levels, wrote the researchers.

They also noted that they observed higher antibody counts in obese participants who have a body mass index of 30 or above.

"Yet, it is still unclear whether vaccinated obese persons are at higher or lower risk for breakthrough infection and whether the relatively high humoral response to the vaccine is protective," the report stated.

خلاصة ما سبق وكل ما يدور منذ عامين أن اللقاح ليس فعالاً طول العمر ولا حتى لسنوات بل وجد أنه حتى من تعاطى الجرعة المحفزة كما يسمونها أو المنشطة أيضاً تتلاشى فاعليتها بعد فترة آي أن كل من أخذ الجرعتين بعد 6 أشهر من الجرعة الثانية وقد يكون بعد 120 يوم فقط تقل المناعة لديه وسيستمر هذا الأمر والسؤال هل سيصبح مثل لقاح الأنفلونزا (الرباعي الآن) أم ماذا؟ كذلك بدأت تجارب كبسولات تعطى لمن أصيب بالمرض في الأيام الأولى (لا يزيد عن 5 أيام) وهي تمنع أنتشار وتكاثر المرض لديه عن طريق تبديل معين يؤدي إلى إعطاء إشارات خاطئة للفايرس عند تكوين مزيد منه فلا يتكاثر ومازال الأمر تحت البحث (ملحوظة أخيرة كل ما أكتبه هنا هو من مواقع طبية ونشرات ومجلات يتم نشرها أو مرئيات ومناقشات أستمع إليها) يعني من الآخر أنا لست طبيباً ولكني أحب القراءة


Tuesday, September 14, 2021

الله المستعان ، الجرعة المحفزة أو المنشطة أو الجرعة الثالثة! آي كان الأسم أصبحت ضرورة ثم الآن التركيز على فايزر جرعة تنشيطية أو مودرنا نصف جرعة! ولا كلام على إسترازنكا



مع قدوم فصل الخريف والشتاء يتسابق العالم في محاولات مواجهة الأنفلونزا الموسمية التي يؤخذ لها لقاح والجرعة المنشطة أو الثالثة

(وليست الأخيرة) لكوفيد 19 ونحن في الموجة (التحور الرابع مو)

اللافت للنظر أن الجميع يأخذ إسرائيل التي تعتبر من أفضل دول العالم في موضوع اللقاح للمواطنين نموذجا يحتذى به حيث التجارب والإرشادات والملاحظات تخرج منها أولاً بل أمريكا تأخذ بقولهم!! والله المستعان ، ثم الملاحظة الثانية أنه تم الأعتراف رسمياً بأن اللقاح تقل فاعليته وقد تنعدم بعد ستة أشهر ، الملاحظة الثالثة هي أن الجرعة الثالثة أو ما يسمى بالتنشيطية تأخذ بالإعتبار أخطاء ونتائج العامين الماضيين ، فالجميع يحاول أن تكون الجرعة من فايزر كاملة أو نصف جرعة من موديرنا (لأن الأعراض للنصف الجرعة أقل) والأبتعاد عن أن تكون الجرعة المنشطة من أسترازنكا والملاحظة الأخيرة هي الجميع يخزن الللقاحات طبعا الدول الغنية ولا يلتفت إلى الدول الفقيرة! والله المستعان كذلك لا كلام على لقاحات الصين وغيرها من اللقاحات التي تكاد تكون معروفة إلا في

https://www.dailymail.co.uk/news/article-9988825/Booster-vaccines-50s.html بعض الدول العربية هذا من مقال في الديلي ميل البريطانية

Government's vaccine advisory panel has recommended third doses be dished out to some 30million people
Plans approved on the back of real-world data in Israel and elsewhere suggesting immunity wanes in months
Britons who are eligible will be given Pfizer's vaccine or a half-dose of the Moderna vaccine


The Government’s vaccine advisory panel recommended a third dose for roughly 30million people aged 50 and over who received their second injection at least six months ago.



Members of the Joint Committee on Vaccination and Immunisation (JCVI) approved the plans on the back of growing real-world data in Israel and elsewhere, as well as a major British study, which suggested vaccine-induced immunity wanes within months.




Britons who are eligible will be given the Pfizer vaccine in the first instance, no matter which jab they were originally immunised with. When there are supply constraints, the Moderna vaccine will be offered as a booster in the form of a half dose.

Officials said there was more evidence that the mRNA vaccines were safe and effective when given as a third dose, which is why they are not recommending AstraZeneca's.

Moderna's is being recommended as a half dose because the lower dosage is associated with fewer side effects and still produces a strong immune response, the JCVI said.

People who are invited for their booster Covid vaccine will be able to get their flu jab at the same time, in the opposite arm.














Professor Wei Shen Lim, of the Joint Committee on Vaccination and Immunisation, said the recommendation of at least a six-month gap between the second jab and a booster shot was an attempt to find an immunity 'sweet spot'.


'We want to suggest a six-month limit as a lower limit because we don’t want people to feel they need to rush to have this booster dose,' he told a Downing Street press conference.

'Getting a booster dose too early might mean getting a dose when they don’t actually need to have vaccination because they still have a high level of protection.

'And, as we have seen with the first and second dose, it may be that a longer interval to the third booster dose may actually be beneficial in the longer term.

'On the other hand, we don’t want to wait too long before offering a booster dose, so trying to find a sweet spot between going too soon and going too late we are suggesting that the booster dose is given no earlier than six months after the second dose.'




Professor Lim said it was preferable for people to get an mRNA vaccine as a booster — such as those made by Pfizer and Moderna — because there was more evidence compared to the AstraZeneca jabs that these are safe and effective.

He told the briefing: 'The AstraZeneca vaccine obviously is a very good vaccine for its primary cause.

'We’ve seen data that suggests that the mRNA vaccines given, whatever the primary cause for the vaccination is, gives a very good boost.




Sunday, August 29, 2021

كل فترة يظهر شئ جديد فايزر مشاكل بالقلب استرازنكا تجلطات بالدم موديرنا عضلة القلب والآن في اليابان إيقاف مودرنا أحترازياً لوفاة شخصين بعد الجرعة الثانية!

 

Two die in Japan after shots from

 suspended Moderna vaccines

 - Japan govt



TOKYO, Aug 28 (Reuters) - Two people died after receiving Moderna COVID-19 vaccine shots that were among lots later suspended following the discovery of contaminants, Japan's health ministry said on Saturday.


The men in their 30s died this month within days of receiving their second Moderna doses, the ministry said in a release. Each had a shot from one of three manufacturing lots suspended on Thursday. The cause of the deaths is still being investigated.

Japan halted the use of 1.63 million Moderna doses https://www.reuters.com/world/asia-pacific/japan-withdraws-16-mln-moderna-covid-19-vaccine-doses-over-contamination-nikkei-2021-08-25 shipped to 863 vaccination centres nationwide, more than a week after the domestic distributor, Takeda Pharmaceutical, received reports of contaminants in some vials.

The government and Moderna had said no safety or efficacy issues had been identified and the suspension was just a precaution.


The contaminant is believed to be metallic particles, Japanese public broadcaster NHK reported, citing health ministry sources.